Study of IMC-1121B in Patients With Advanced Solid Tumors

Inclusion Criteria:

* Solid tumor participant who was been histopathologically or cytologically documented.
* Advanced primary or recurrent solid tumors participant who has not responded to standard therapy or no standard therapy is available.
* The participant has measurable or nonmeasurable lesions according to Response Evaluation Criteria in Solid Tumors (RECIST).
* The participant has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1 at study entry.
* The participant is able to provide written informed consent.
* The participant is age 20 years or older.
* The participant has a life expectancy of \> 3 months.
* The participant has adequate hematologic function, as defined by:
* An absolute neutrophil count (ANC) \> 1500/cubic millimeter (mm³) or /microliter (µL)
* A hemoglobin level \> 10 grams/deciliter (g/dL)
* A platelet count \> 100,000/mm³ or /µL
* The participant has adequate hepatic function, as defined by:
* A total bilirubin level \< 1.8 milligrams/deciliter (mg/dL)
* Aspartate transaminase (AST) levels \< 86 International Units/liter (IU/L)
* Alanine transaminase (ALT) levels ≤ 86 IU/L
* The participant has adequate renal function, as defined by:
* Serum creatinine level ≤ 1.5 mg/dL, or
* Calculated serum creatinine clearance (Cockcroft-Gault) ≥ 60 milliliters/minute (mL/min)
* The participant's urinary protein is 0 on dipstick or 1+ but participant does not have edema nor serum albumin \< lower level of normal (LLN).
* The participant has adequate coagulation function, as defined by international normalized ratio (INR) ≤ 1.5.
* The participant agrees to use adequate contraception during the study period and for 12 weeks after the last dose of study treatment.

Exclusion Criteria:

* The participant has had chemotherapy or therapeutic radiotherapy within 28 days (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or participant has ongoing side effects ≥ Grade 2 due to agents administered more than 28 days earlier.
* The participant has obvious evidence of intratumor cavitation.
* The participant has undergone major surgery (example, laparotomy, thoracotomy, removal of organ\[s\]) within 28 days prior to study entry, or subcutaneous venous access device placement within 7 days prior to study entry.
* The participant has a history of postoperative bleeding complications or wound complications from a surgical procedure.
* The participant has elective or planned surgery to be conducted during the trial.
* The participant has documented and/or symptomatic brain or leptomeningeal metastases. (Participants who are clinically stable \[no symptoms during 4 weeks prior to the enrollment\] with an assessment that no further treatment \[radiation, surgical excision, and administration of steroids\] is required, are permitted to enter the study.)
* The participant has uncontrolled intercurrent illness including, but not limited to:
* Thrombotic or hemorrhagic disorders
* Hemoptysis (approximately one-half of a teaspoon)
* Ongoing or active infection requiring systemic antibiotic treatment
* Congestive heart failure (Class III or IV of the New York Heart Association classification for heart disease)
* Angina pectoris, angioplasty, stenting, or myocardial infarction within 6 months
* Uncontrolled hypertension (systolic blood pressure \> 150 millimeters of mercury (mmHg), diastolic blood pressure \> 95 mm Hg)
* Cardiac arrhythmia requires treatment \[National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 (NCI-CTCAE v 3.0), Grade 3\], or asymptomatic sustained ventricular tachycardia)
* Peripheral neuropathy of any etiology ≥ Grade 2 (NCI-CTCAE v 3.0)
* The participant has participated in clinical studies of non-approved experimental agents or procedures within 4 weeks prior to study entry for small molecules, or 8 weeks prior to study entry for non-approved monoclonal antibodies.
* The participant, if female, is pregnant (confirmed by urine or serum pregnancy test) or lactating.